Climb Bio (CLYM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Climb Bio (CLYM) is Neutral.

The composite score behind that read is -0.13, weighing +0.16 of bullish evidence against -0.24 bearish.

Climb Bio last closed at $11.05, +1.01% on the session.

Against the IVW growth benchmark the position is +0.09% over the forecast window.

The read is built from 11 underlying insights — 4 bullish and 7 bearish.

Agreement across those insights is 64%.

Climb Bio has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Climb Bio in the 23rd percentile on return on equity, where 100 is best.

Climb Bio is classified under Health Care / Biotechnology, with a market capitalisation of $628.35M.

StockMap tracks Climb Bio as the 155th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Climb Bio ranks 87th of 344 in the group, against a group median of -0.21.